Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824567 | 0.86 | HTT (0.75) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL9842944 | 0.85 | POLB (0.77) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13746214 | 0.84 | HTT (0.73) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL9312707 | 0.83 | POLB (1.00) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL8986265 | 0.83 | POLB (0.73) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL11247219 | 0.83 | POLB (0.73) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12445438 | 0.82 | POLB (0.83) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12310179 | 0.81 | POLB (0.71) | HTTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL25086 | 0.80 | POLB (0.80) | HTTALDH1A1MEN1KMT2APOLB | |
| Fenacetinol SCHEMBL2850567 | 0.80 | POLB (0.80) | HTTALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | NLN, GAP43, AIFM1 | HTT 250/4885ALDH1A1 1691/4885MEN1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.